Summary
Chugai Pharmaceutical Co Ltd (Chugai), a subsidiary of Hoffmann-La Roche Ltd, is a provider of biopharmaceuticals and therapeutic antibodies. The company offers products for the treatment of cancer; bone and joint diseases; renal diseases; immunology and infectious diseases and others. It also offers drugs to aid kidney, liver and other organ transplantations. Chugai's major products include Avastin (bevacizumab), Herceptin (trastuzumab), Rituxan (rituximab), Actemra (tocilizumab), Edirol (eldecalcitol) and Mircera (epoetin beta pegol). It also has a range of product candidates in its pipeline. The company offers its pharmaceutical products in overseas markets including North America, Europe and Asia. Chugai is headquartered in Tokyo, Japan.
Chugai Pharmaceutical Co Ltd (4519) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Chugai Pharmaceutical Co Ltd, Medical Devices Deals, 2011 to YTD 2017 11
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 15
Partnerships 15
Helsinn Enters into Licensing Agreement with Chugai Pharma for Netupitant-Palonosetron Fixed-Dose Combination 15
Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 15
Chugai Pharmaceutical Enters into Agreement with Osaka University 17
Chugai Pharma Enters Into Co-Development Agreement With Nippon Shinyaku For GA101 18
Schnell BioPharma Enters Into Co-Development Agreement With Aprogen And Chunggei Pharm 19
Licensing Agreements 20
JW Pharma Enters into Licensing Agreement with Chugai Pharma 20
Chugai Pharma Enters into Licensing Agreement with SBI Pharma 21
Chugai Pharma Enters into Licensing Agreement with Pharma Mar 22
Berlin-Chemie Enters into Licensing Agreement with Chugai Pharma 23
Maruho Enters into Licensing Agreement with Chugai Pharma 23
Galderma Pharma to Enter into Licensing Agreement with Chugai Pharma 24
Roche Enters into Licensing Agreement with Chugai Pharma for Recycling Antibody SA237 25
Chugai Pharma Enters into Licensing Agreement with Two Cells 26
BioMarin Pharma Enters into Sub-license Agreement with Chugai Pharma 26
Kowa Company Enters into Licensing Agreement with Chugai Pharmaceutical 27
EpiVax Enters into Licensing Agreement with Chugai Pharma 28
Roche Amends Licensing Agreement with Chugai Pharma 29
PharmaMar Enters into Licensing Agreement with Chugai Pharma for Aplidin 30
Chugai Pharma Enters into Licensing Agreement with Roche 31
Helsinn Enters Into Licensing Agreement With Chugai Pharma Marketing For Anamorelin 32
Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 32
Chugai Pharma Expands Licensing Agreement with Kowa for DEBERZA 33
Chugai Pharma Extends Licensing Agreement With Genedata For Genedata Expressionist Software 35
Chugai Pharma Enters Into Licensing Agreement With Roche For MetMAb And Lebrikizumab 36
Chugai Pharma Enters Into Licensing Agreement With Roche For Vemurafenib 36
Asset Transactions 38
Eisai Acquires Rights to Manufacture Active Pharmaceutical Ingredients in Japan from Chugai Pharma and F. Hoffman-La Roche 38
Acquisition 39
Roche May Acquire 40% Stake in Chugai Pharma 39
Chugai Pharmaceutical Co Ltd - Key Competitors 40
Key Employees 41
Locations And Subsidiaries 43
Head Office 43
Other Locations & Subsidiaries 43
Recent Developments 46
Strategy And Business Planning 46
Jan 27, 2017: Aiming to Provide Solutions that Meet Changes of Regional Healthcare Services 46
Product News 47
Nov 03, 2016: Genentech to present data on Emicizumab at American Society of Hematology 2016 Annual Meeting 47
Jul 27, 2016: Chugai Emicizumab Showed Continued Benefits in Patients with Hemophilia A 48
Product Approvals 49
Aug 26, 2016: Chugai receives Orphan Drug Designation for Emicizumab - Preventing and Reducing the Frequency of Bleeding Episodes in Congenital FVlll Deficiency Patients with Inhibitors 49
Clinical Trials 50
Mar 02, 2017: Chugai’s Anti-IL-31 Receptor A Humanized Monoclonal Antibody “nemolizumab (CIM331)” Global Phase II Study Data Published in The New England Journal of Medicine Online 50
Dec 22, 2016: Chugai’s Bispecific Antibody Emicizumab for Hemophilia A Meets Primary Endpoint in Phase lll Study - emicizumab prophylaxis shown to reduce bleeding in patients with inhibitors 51
May 25, 2016: Chugai's Bispecific Antibody "ACE910/Emicizumab" Phase l Data in Patients with Hemophilia A Published in The New England Journal of Medicine Online 52
Mar 05, 2016: Chugai Announces Phase II Global Study Results of Nemolizumab (CIM331) in Late-breaking Research Forums at AAD 53
Other Significant Developments 54
Apr 04, 2017: A First Approach in the Japanese Pharmaceutical Industry Starting a Trial of a Drug Adherence Support App Using Multidisciplinary SNS for Outpatient Cancer Treatment 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55
List of Tables
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Chugai Pharmaceutical Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 9
Chugai Pharmaceutical Co Ltd, Medical Devices Deals, 2011 to YTD 2017 11
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Helsinn Enters into Licensing Agreement with Chugai Pharma for Netupitant-Palonosetron Fixed-Dose Combination 15
Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 15
Chugai Pharmaceutical Enters into Agreement with Osaka University 17
Chugai Pharma Enters Into Co-Development Agreement With Nippon Shinyaku For GA101 18
Schnell BioPharma Enters Into Co-Development Agreement With Aprogen And Chunggei Pharm 19
JW Pharma Enters into Licensing Agreement with Chugai Pharma 20
Chugai Pharma Enters into Licensing Agreement with SBI Pharma 21
Chugai Pharma Enters into Licensing Agreement with Pharma Mar 22
Berlin-Chemie Enters into Licensing Agreement with Chugai Pharma 23
Maruho Enters into Licensing Agreement with Chugai Pharma 23
Galderma Pharma to Enter into Licensing Agreement with Chugai Pharma 24
Roche Enters into Licensing Agreement with Chugai Pharma for Recycling Antibody SA237 25
Chugai Pharma Enters into Licensing Agreement with Two Cells 26
BioMarin Pharma Enters into Sub-license Agreement with Chugai Pharma 26
Kowa Company Enters into Licensing Agreement with Chugai Pharmaceutical 27
EpiVax Enters into Licensing Agreement with Chugai Pharma 28
Roche Amends Licensing Agreement with Chugai Pharma 29
PharmaMar Enters into Licensing Agreement with Chugai Pharma for Aplidin 30
Chugai Pharma Enters into Licensing Agreement with Roche 31
Helsinn Enters Into Licensing Agreement With Chugai Pharma Marketing For Anamorelin 32
Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 32
Chugai Pharma Expands Licensing Agreement with Kowa for DEBERZA 33
Chugai Pharma Extends Licensing Agreement With Genedata For Genedata Expressionist Software 35
Chugai Pharma Enters Into Licensing Agreement With Roche For MetMAb And Lebrikizumab 36
Chugai Pharma Enters Into Licensing Agreement With Roche For Vemurafenib 36
Eisai Acquires Rights to Manufacture Active Pharmaceutical Ingredients in Japan from Chugai Pharma and F. Hoffman-La Roche 38
Roche May Acquire 40% Stake in Chugai Pharma 39
Chugai Pharmaceutical Co Ltd, Key Competitors 40
Chugai Pharmaceutical Co Ltd, Key Employees 41
Chugai Pharmaceutical Co Ltd, Other Locations 43
Chugai Pharmaceutical Co Ltd, Subsidiaries 44List of Figures
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Chugai Pharmaceutical Co Ltd, Medical Devices Deals, 2011 to YTD 2017 11
